FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is application of neuroleptic haloperidol as means able to prevent development of abnormalities in lung tissue, caused by introduction of cytostatics. Reduction in development of inflammatory response due to reduction of development of connective tissue (pneumofibrosis) in lungs at the background of bleomicin introduction is shown.
EFFECT: invention can be applied for pharmacological correction of abnormalities in lung tissue developing with administration of anti-tumour medications.
1 dwg, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR IMPROVING THERAPEUTIC EFFECTIVENESS IN LUNG TISSUE DISORDERS AFTER ACTION OF CYTOSTATICS | 2012 |
|
RU2497523C1 |
AGENT PREVENTING DEVELOPING DISORDERS IN PULMONARY TISSUE AND BLOOD SYSTEM ACCOMPANYING CYTOSTATIC ACTION | 2011 |
|
RU2464983C1 |
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2012 |
|
RU2479312C1 |
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
METHOD OF TREATING PULMONARY FIBROSIS | 2012 |
|
RU2494470C1 |
AGENT FOR CORRECTING PULMONARY TISSUE DISORDERS UNDER CYTOSTATIC EXPOSURE | 2013 |
|
RU2554776C1 |
MEANS FOR PNEUMOFIBROSIS PREVENTION AND TREATMENT AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2646810C1 |
DRUG POSSESSING REGENERATIVE ACTIVITY | 2011 |
|
RU2480236C1 |
BISAMIDE DERIVATIVE OF DICARBOXYLIC ACID AS AGENT STIMULATING TISSUE REGENERATION AND RESTORATION OF REDUCED FUNCTIONS OF TISSUES | 2016 |
|
RU2727142C2 |
METHOD OF DIAGNOSING STAGE OF PLEURAL EMPIEMA | 2009 |
|
RU2400752C1 |
Authors
Dates
2012-07-20—Published
2011-07-05—Filed